Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 349438-38-6 Chemical Structure| 349438-38-6

Structure of Alda-1
CAS No.: 349438-38-6

Chemical Structure| 349438-38-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Alda-1 is a potent and selective ALDH2 agonist that activates wild-type ALDH2 and restores near wild-type activity to ALDH2*2.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Alda-1

CAS No. :349438-38-6
Formula : C15H11Cl2NO3
M.W : 324.16
SMILES Code : O=C(NCC1=CC=C(OCO2)C2=C1)C3=C(Cl)C=CC=C3Cl
MDL No. :MFCD02055160
InChI Key :NMKJFZCBCIUYHI-UHFFFAOYSA-N
Pubchem ID :831629

Safety of Alda-1

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H301-H400
Precautionary Statements:P273-P301+P310
Class:6.1
UN#:2811
Packing Group:

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
recombinant ALDH2 20 μM 1 hour Alda-1 prevented nitroglycerin-induced ALDH2 inactivation PMC3547591
H9c2 cells 20 μM 12 hours Alda-1 treatment significantly increased ALDH2 activation in H9c2 cells and promoted mitochondrial respiration. PMC7809100
cardiomyocytes 20 μM 12 hours Alda-1 treatment significantly increased ALDH2 activation in cardiomyocytes and promoted mitochondrial respiration. PMC7809100
T84 human colon cells 20 μM 12 hours Alda-1 restored the levels of ALDH2 protein and activity, and significantly blocked ethanol-induced increase in cell permeability and reduction in TJ/AJ protein levels. PMC9792909
A549 cells 0 nM, 100 nM, 350 nM, 1 μM 2 days Alda-1 treatment significantly reduced the side population of A549 cells, indicating that Alda-1 inhibits the stem cell-like properties of lung cancer cells. PMC6506700
H1299 cells 0 nM, 100 nM, 1 μM 2 days Alda-1 treatment significantly reduced the CD44+/CD24? population of H1299 cells, indicating that Alda-1 inhibits the stem cell-like properties of lung cancer cells. PMC6506700
H9C2 cells 20 μM 2 hours To evaluate the protective effect of Alda-1 on LPS-induced apoptosis and inflammation in H9C2 cells, the results showed that Alda-1 pretreatment significantly reduced LPS-induced mitochondrial membrane permeability, ROS levels, and apoptosis rate, and decreased the expression of inflammatory factors. PMC10731778
H9C2 myoblasts 20 μM 24 hours To evaluate the protective effect of Alda-1 on Aβ-induced lipid peroxidation, results showed that Alda-1 significantly alleviated Aβ-induced lipid peroxidation. PMC8724276
Human renal proximal tubular epithelial cells (HK-2) 20μM 24 hours To evaluate the effect of Alda-1 on MA-induced mitochondrial dysfunction and apoptosis in HK-2 cells. Results showed that Alda-1 treatment significantly improved mitochondrial function and reduced apoptosis. PMC9860042
H4IIEC3 rat hepatoma cells 100 μM acetaldehyde or 10 μM 4-HNE 3 days To define the link between aldehydes and hepatotoxicity, results showed that acetaldehyde or 4-HNE treatment caused transcription factor inactivation, ER stress, and apoptosis. PMC7949737
3T3 cells 20 µM 48 hours Evaluate the activation effect of Alda-1 on ALDH2 variants. The results showed that Alda-1 increased the activity of the ALDH2*2 variant by approximately 14-fold, but had limited activation effects on other variants. PMC7218264
Human-derived fibroblasts 20 µM 48 hours Evaluate the activation effect of Alda-1 on ALDH2 variants. The results showed that Alda-1 had poor activation effects on ALDH2*3 and ALDH2*6 variants, and did not significantly improve their activity. PMC7218264
Cardiac fibroblasts 20 µM 96 hours Alda-1 treatment reduced fibroblast proliferation under aldehydic load stress PMC4155470
ALDH2*1 0.03–0.06 μM To study the activation effect of Alda-1 on ALDH2*1 dehydrogenase activity PMC2857674
ALDH2*2 0.3–0.5 μM To study the activation effect of Alda-1 on ALDH2*2 dehydrogenase activity PMC2857674
HepG2 cells 40 μM Alda-1 prevented HNE-induced HepG2 cell death by activating ALDH2 to degrade HNE PMC9500440
Huh-7 cells 40 μM Alda-1 prevented HNE-induced Huh-7 cell death by activating ALDH2 to degrade HNE PMC9500440

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice Alcoholic liver disease model Intraperitoneal injection 5 mg/kg body weight Every other day for 10 days To test the therapeutic potential of Alda-1 for alcoholic liver disease, results showed that Alda-1 treatment alleviated liver damage, reduced hepatic steatosis, and apoptosis. PMC7949737
Mouse GSNO-R−/− mice Perfusion 20 μmol/L 10 minutes prior to the onset of ischemia and for 10 minutes at the start of reperfusion Alda-1 significantly reduced infarct size in female GSNO-R?/? hearts, suggesting that excess mitochondrial formaldehyde may exacerbate I/R injury in female hearts with the disruption of GSNO-R. PMC6310045
Mice and rats ALDH2*1/*2 knock-in mice and Wistar rats Subcutaneous injection 2 mg/kg 15 minutes before, and again at 30 and 150 minutes after Alda-1 reduced the response to nociceptive stimulus in ALDH2*1/*2 mice and reversed the carrageenan-induced pain behavior, restoring thresholds to baseline values for both wild type and ALDH2*1/*2 mice. PMC4234033
Wistar rats myocardial infarction model continuous infusion via Alzet pump 16 mg/kg/day 16 hours Alda-1 prevented nitroglycerin-induced increase in myocardial infarction injury PMC3547591
C57BL/6J mice GFP-LC3 transgenic mice Intraperitoneal injection 50 mg/kg Single dose Alda-1 pretreatment reduced ethanol-induced mitochondrial depolarization and GFP-LC3 puncta formation. PMC9629059
Rats Myocardial infarction-induced heart failure model Subcutaneous injection 10 mg/kg/day Continuous for 6 weeks Alda-1 treatment improved cardiac function, reduced left ventricular dilation, and decreased myocardial hypertrophy and cardiac fibrosis PMC4155470
C57BL/6 mice Bile duct ligation model Subcutaneous injection 20 mg/kg Once daily for 14 days Alda-1 accelerates aldehyde degradation by activating ALDH2, reducing BDL-induced liver necrosis, inflammation, and fibrosis, indicating that aldehydes play an important role in the pathogenesis of cholestatic liver injury and fibrosis. PMC6880805
Mice Choline-deficient, amino acid-defined (CDAA) mouse model Intraperitoneal injection 20 mg/kg 3 times a week for 8 weeks Alda-1 reduced liver inflammation and fibrosis by degrading HNE PMC9500440
C57BL/6 mice Cisplatin or maleic acid-induced acute kidney injury model Intraperitoneal injection 20 mg/kg Once daily for 3 days To evaluate the protective effect of Alda-1 on cisplatin or maleic acid-induced acute kidney injury. Results showed that Alda-1 pretreatment significantly improved renal function and reduced tubular injury and apoptosis. PMC9860042
C57BL/6 mice Intestinal ischemia-reperfusion injury model Intraperitoneal injection 10 mg/kg Single dose, 1 hour before ischemia Alda-1 pretreatment significantly alleviated intestinal ischemia-reperfusion injury, accompanied by up-regulated ALDH2 activity and reduced accumulation of 4-HNE and MDA. PMC5434792
C57BL/6 mice LPS-induced myocardial injury model intraperitoneal injection 10 mg/kg single injection, lasting 12 hours To evaluate the protective effect of Alda-1 on LPS-induced cardiac dysfunction, inflammation, and apoptosis, the results showed that Alda-1 pretreatment significantly improved cardiac function, reduced the expression of cardiac injury markers CKMB and LDH, and decreased the levels of inflammatory cytokines and apoptosis rate. PMC10731778

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.08mL

0.62mL

0.31mL

15.42mL

3.08mL

1.54mL

30.85mL

6.17mL

3.08mL

References

 

Historical Records

Categories